World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 112 5072 4758 2744 2542 855 58939

Scott Kopetz publications per year

The chart shows the history of publications by Scott Kopetz between 1999 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Scott Kopetz published across 27 years, from 1999 to 2025, averaging 63.2 papers a year. Output peaked at 587 publications in 2023. 317 of the 1,707 publications appeared in the last two years.

No. of publications
100 200 300 400 500
Bar chart. Horizontal axis: year, 1999 to 2025. Vertical axis: number of publications, 0 to 587. Peak 587 publications in 2023. 1999: 1 publication 2000: 1 publication 2001: 0 publications 2002: 0 publications 2003: 0 publications 2004: 0 publications 2005: 3 publications 2006: 3 publications 2007: 6 publications 2008: 21 publications 2009: 14 publications 2010: 14 publications 2011: 23 publications 2012: 28 publications 2013: 42 publications 2014: 38 publications 2015: 59 publications 2016: 49 publications 2017: 93 publications 2018: 73 publications 2019: 83 publications 2020: 73 publications 2021: 69 publications 2022: 110 publications 2023: 587 publications 2024: 276 publications 2025: 41 publications
1999 2025

1,707 publications in total across all disciplines

View publications per year as a table
Scott Kopetz: publications per year, 1999 to 2025
Year Publications
1999 1
2000 1
2001 0
2002 0
2003 0
2004 0
2005 3
2006 3
2007 6
2008 21
2009 14
2010 14
2011 23
2012 28
2013 42
2014 38
2015 59
2016 49
2017 93
2018 73
2019 83
2020 73
2021 69
2022 110
2023 587
2024 276
2025 41
Total 1,707
Download as CSV

Scott Kopetz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Scott Kopetz sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 841–860 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 855 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177 855
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Scott Kopetz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Scott Kopetz sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 112–113 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399 112
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Scott Kopetz is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine with extensive contributions in oncology and biochemistry, genetics, and molecular biology.

The scientist has published extensively in subfields such as oncology, cancer research, pathology and forensic medicine, molecular biology, and pulmonary and respiratory medicine. Their work covers many topics including colorectal cancer treatments and studies, cancer genomics and diagnostics, genetic factors in colorectal cancer, lung cancer treatments and mutations, cancer immunotherapy and biomarkers, gastric cancer management and outcomes, and cancer treatment and pharmacology.

Notable recent papers include:

  • Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study, 2021, Journal of Clinical Oncology
  • Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406), 2020, Journal of Clinical Oncology
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper, 2020, Nature Reviews Clinical Oncology
  • Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility, 2020, Gut
  • Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142, 2022, Annals of Oncology

Scott Kopetz frequently collaborates with several researchers, including:

  • Michael J. Overman
  • Van K. Morris
  • Kanwal Raghav
  • John Paul Shen
  • Benny Johnson

Their work has appeared in multiple scientific venues, with prominent publications in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Clinical Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • The consensus molecular subtypes of colorectal cancer

    Justin Guinney;Rodrigo Dienstmann;Rodrigo Dienstmann;Xingwu Wang;Xingwu Wang;Aurélien De Reyniès

  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

    Michael J. Overman;Ray McDermott;Joseph L. Leach;Sara Lonardi

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

    Scott Kopetz;George J. Chang;Michael J. Overman;Cathy Eng

  • Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

    Jérôme Galon;Jérôme Galon;Jérôme Galon;Bernhard Mlecnik;Bernhard Mlecnik;Bernhard Mlecnik;Gabriela Bindea;Gabriela Bindea;Gabriela Bindea;Helen K. Angell;Helen K. Angell;Helen K. Angell

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • Cancer classification using the Immunoscore: a worldwide task force

    Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  • Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    Rodrigo Dienstmann;Louis Vermeulen;Justin Guinney;Scott Kopetz

  • Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

    Ben Tran;Scott Kopetz;Jeanne Tie;Peter Gibbs

  • Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

    Scott Kopetz;Jayesh Desai;Emily Chan;Joel Randolph Hecht

  • Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

    Dan G. Blazer;Yoji Kishi;Dipen M. Maru;Scott Kopetz

  • CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

    Hui Ling;Riccardo Spizzo;Yaser Atlasi;Milena Nicoloso

  • Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

    Yun Shin Chun;Jean Nicolas Vauthey;Piyaporn Boonsirikamchai;Dipen M. Maru

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

    T. Yoshino;D. Arnold;H. Taniguchi;G. Pentheroudakis

  • KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer

    Wenting Liao;Michael J. Overman;Adam T. Boutin;Xiaoying Shang

  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

    Scott Kopetz;Paulo M. Hoff;Jeffrey S. Morris;Robert A. Wolff

  • Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals from 2008 to 2018

    Jonathan M. Loree;Seerat Anand;Arvind Dasari;Joseph M. Unger

  • Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

    Funda Meric-Bernstam;Lauren Brusco;Kenna Shaw;Chacha Horombe

  • High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome

    Antoine Brouquet;Eddie K. Abdalla;Scott Kopetz;Christopher R. Garrett

Frequent Co-Authors

Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Cathy Eng
Cathy Eng Vanderbilt University
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Robert A. Wolff
Robert A. Wolff The University of Texas MD Anderson Cancer Center
Jean Nicolas Vauthey
Jean Nicolas Vauthey The University of Texas MD Anderson Cancer Center
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Russell Broaddus
Russell Broaddus University of North Carolina at Chapel Hill
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
George J. Chang
George J. Chang The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in expanding your healthcare career options beyond traditional medicine? There are several flexible online pathways to consider. For example, direct msn programs online allow individuals without a nursing background to earn a Master of Science in Nursing, often in less time than traditional routes.

If you're looking to become a nurse quickly, some schools offer an easiest bsn program to get into, making the transition into nursing more accessible for those with varying academic backgrounds.

For students who prefer working in the medical field without direct patient care, medical billing and coding is a rapidly growing area. You can find accredited remote programs offering financial aid for medical billing and coding, making these skills attainable and affordable.

In addition, some prospective nurses seek out nursing programs without teas or other standardized exam requirements, streamlining entry into nursing school.

Best Scientists Citing Scott Kopetz

Trending Scientists

Recently Published Articles